PortalPublikationenA new case with rare e6a2 BCR-ABL fusion transcript developi...

A new case with rare e6a2 BCR-ABL fusion transcript developing two new resistance mutations during imatinib mesylate, which were replaced by T315I after subsequent dasatinib treatment.

Standard

A new case with rare e6a2 BCR-ABL fusion transcript developing two new resistance mutations during imatinib mesylate, which were replaced by T315I after subsequent dasatinib treatment. / Schnittger, S; Bacher, Ulrike; Kern, W; Haferlach, T; Hertenstein, B; Haferlach, C.

in: LEUKEMIA, Jahrgang 22, Nr. 4, 4, 2008, S. 856-858.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Schnittger, S, Bacher, U, Kern, W, Haferlach, T, Hertenstein, B & Haferlach, C 2008, 'A new case with rare e6a2 BCR-ABL fusion transcript developing two new resistance mutations during imatinib mesylate, which were replaced by T315I after subsequent dasatinib treatment.', LEUKEMIA, Jg. 22, Nr. 4, 4, S. 856-858. <http://www.ncbi.nlm.nih.gov/pubmed/17851552?dopt=Citation>

APA

Schnittger, S., Bacher, U., Kern, W., Haferlach, T., Hertenstein, B., & Haferlach, C. (2008). A new case with rare e6a2 BCR-ABL fusion transcript developing two new resistance mutations during imatinib mesylate, which were replaced by T315I after subsequent dasatinib treatment. LEUKEMIA, 22(4), 856-858. [4]. http://www.ncbi.nlm.nih.gov/pubmed/17851552?dopt=Citation

Vancouver

Schnittger S, Bacher U, Kern W, Haferlach T, Hertenstein B, Haferlach C. A new case with rare e6a2 BCR-ABL fusion transcript developing two new resistance mutations during imatinib mesylate, which were replaced by T315I after subsequent dasatinib treatment. LEUKEMIA. 2008;22(4):856-858. 4.

Bibtex

@article{583bb443a5a94df495c0a3de17c75002,
title = "A new case with rare e6a2 BCR-ABL fusion transcript developing two new resistance mutations during imatinib mesylate, which were replaced by T315I after subsequent dasatinib treatment.",
author = "S Schnittger and Ulrike Bacher and W Kern and T Haferlach and B Hertenstein and C Haferlach",
year = "2008",
language = "Deutsch",
volume = "22",
pages = "856--858",
journal = "LEUKEMIA",
issn = "0887-6924",
publisher = "NATURE PUBLISHING GROUP",
number = "4",

}

RIS

TY - JOUR

T1 - A new case with rare e6a2 BCR-ABL fusion transcript developing two new resistance mutations during imatinib mesylate, which were replaced by T315I after subsequent dasatinib treatment.

AU - Schnittger, S

AU - Bacher, Ulrike

AU - Kern, W

AU - Haferlach, T

AU - Hertenstein, B

AU - Haferlach, C

PY - 2008

Y1 - 2008

M3 - SCORING: Zeitschriftenaufsatz

VL - 22

SP - 856

EP - 858

JO - LEUKEMIA

JF - LEUKEMIA

SN - 0887-6924

IS - 4

M1 - 4

ER -